The final episode of this series looks at what happens to the brain when someone uses psychedelic drugs. It looks at how psychedelic drugs may be useful in dealing with anxiety in cancer survivors and serious depression. It explores the history of psychedelics and examines early medical experimentation with the drug. It also discussed why psychedelics were banned and examines how they affect the brain.

This highly anticipated psychedelic docuseries showcases what these substances teaches people about consciousness, dying, addiction, depression and transcendence. Filmmaker Alex Gibney and best-selling author Michael Pollan present it in four parts, each focused on a different mind-altering substance: LSD, psilocybin, MDMA, and mescaline. With Pollan as our guide, we journey to the frontiers of the new psychedelic renaissance -- and look back at almost-forgotten historical context -- to explore the potential of these substances to heal and change minds as well as culture.
The first chapter is a great introduction to the topic of LSD, from its 1943 origins to today's microdosing trend, for those who don’t already know a lot about the subject, and a fun and entertaining refresher on LSD for even experts in the field. The show takes us on a journey through the history of the powerful compound, from its discovery and its early medical use, to secret CIA mind-control studies, the counterculture and its banning, and finally to our current renaissance. It includes amazing clips of LSD’s inventor Albert Hofmann and powerful personal testimonies of individuals who have healed their suffering through LSD.

Magic mushrooms, long considered sacred by the Indigenous Mazatec in Mexico, become the subject of scientific studies measuring the intense effects of its Psilocybin and its potential therapeutic use.
In the second episode, we are introduced to Ben, who’s battled with crippling Obsessive-Compulsive Disorder (OCD) his entire life. When he had his firstborn, Ben’s life became full of panic attacks regarding his son’s safety, and he knew something had to change. Ben signed up for a psilocybin-assisted therapy clinical trial which was testing whether the psychedelic could help people with severe OCD. In the session under the influence of psilocybin, Ben felt decomposed and eventually grew into a tree. While living as a tree, he saw his human self, playing with his child. Though this sounds scary, from Ben’s perspective, it was beautiful. He was one with the universe, seeing himself in the ultimate third-person perspective. Finally, he saw how it could be different if he didn’t let his OCD control him. And several months out, all the symptoms disappeared.
Ben’s story is one of many told in this series, which gives hope that help is right around the corner for the millions who suffer —often in silence— with debilitating mental disorders. But Michael Pollan’s work is showcasing the success stories. Often, even in the most successful trials, psychedelic-assisted therapy only helps up to a third of people enter remission. More frequently, patients are helped —sometimes substantially— but they still suffer with their illnesses and some people aren’t helped at all.

Principles of generosity and prosperity inform the selection of the last two crew members: Christopher Sembroski, a former member of the U.S. Air Force who served in Iraq and now works as a Lockheed Martin engineer, and Sian Proctor, a professor of geosciences and two-time NASA astronaut candidate. Excitement for the flight ramps up, but anxiety lingers.

Championed by both therapists and ravers, ecstasy stands out as the first psychedelic likely to become legalized, thanks to passionate advocates.
The episode about 3,4-Methylenedioxymethamphetamine (MDMA), is focused on Multidisciplinary Association for Psychedelic Studies (MAPS) clinical trials treating Post-traumatic stress disorder (PTSD).